Literature DB >> 22495072

Elevated levels of RhoA in the optic nerve head of human eyes with glaucoma.

Brian Goldhagen1, Alan D Proia, David L Epstein, Ponugoti Vasantha Rao.   

Abstract

PURPOSE: To determine changes in the expression profile of RhoA and Rho kinase (ROCK-1 and ROCK-2) in the aqueous humor outflow pathway and optic nerve head (ONH) of human eyes with or without glaucoma to explore their potential involvement in glaucoma pathophysiology.
METHODS: Age-matched paraffin-embedded postmortem eyes from patients with or without glaucoma were stained immunohistochemically using polyclonal antibodies raised against RhoA, ROCK-1, and ROCK-2. The intensity of the immunostaining in the aqueous humor outflow pathway and the ONH was graded by 4 individuals who were masked concerning whether the eyes were from normal individuals or those with glaucoma.
RESULTS: Both normal eyes and those with glaucoma showed a positive staining for RhoA, ROCK-1, and ROCK-2 in the trabecular meshwork, ciliary muscle, and ONH. There was a significant increase in the RhoA protein levels in the glaucomatous ONH compared with the age-matched controls.
CONCLUSIONS: Elevated levels of RhoA in the ONH of glaucomatous eyes suggest possible involvement of RhoA in the pathophysiology of glaucoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22495072     DOI: 10.1097/IJG.0b013e318241b83c

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  24 in total

Review 1.  Rho kinase inhibitors-a review on the physiology and clinical use in Ophthalmology.

Authors:  Nuno Moura-Coelho; Joana Tavares Ferreira; Carolina Pereira Bruxelas; Marco Dutra-Medeiros; João Paulo Cunha; Rita Pinto Proença
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-03-07       Impact factor: 3.117

2.  Lentiviral Vector-Mediated Expression of Exoenzyme C3 Transferase Lowers Intraocular Pressure in Monkeys.

Authors:  Junkai Tan; Guo Liu; Xianjun Zhu; Zhijian Wu; Ningli Wang; Liang Zhou; Xiaoguang Zhang; Ning Fan; Xuyang Liu
Journal:  Mol Ther       Date:  2019-05-09       Impact factor: 11.454

Review 3.  Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma.

Authors:  Megumi Honjo; Hidenobu Tanihara
Journal:  Jpn J Ophthalmol       Date:  2018-02-14       Impact factor: 2.447

Review 4.  Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research.

Authors:  Ponugoti Vasantha Rao; Padmanabhan P Pattabiraman; Casey Kopczynski
Journal:  Exp Eye Res       Date:  2016-09-01       Impact factor: 3.467

Review 5.  Discovery of novel inhibitors for the treatment of glaucoma.

Authors:  Kishore Cholkar; Hoang M Trinh; Dhananjay Pal; Ashim K Mitra
Journal:  Expert Opin Drug Discov       Date:  2015-01-09       Impact factor: 6.098

Review 6.  Status of Rho kinase inhibitors in glaucoma therapeutics-an overview.

Authors:  Bhawesh Chandra Saha; Rashmi Kumari; Rakhi Kushumesh; Anita Ambasta; Bibhuti Prasanna Sinha
Journal:  Int Ophthalmol       Date:  2021-08-27       Impact factor: 2.031

7.  RhoA GTPase-induced ocular hypertension in a rodent model is associated with increased fibrogenic activity in the trabecular meshwork.

Authors:  Padmanabhan P Pattabiraman; Tommy Rinkoski; Eric Poeschla; Alan Proia; Pratap Challa; Ponugoti V Rao
Journal:  Am J Pathol       Date:  2014-12-12       Impact factor: 4.307

8.  RKI-1447, a Rho kinase inhibitor, causes ocular hypotension, actin stress fiber disruption, and increased phagocytosis.

Authors:  Yalong Dang; Chao Wang; Priyal Shah; Susannah Waxman; Ralitsa T Loewen; Nils A Loewen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-11-19       Impact factor: 3.117

Review 9.  Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension.

Authors:  Angelo P Tanna; Mark Johnson
Journal:  Ophthalmology       Date:  2018-07-12       Impact factor: 12.079

Review 10.  [Rho kinase inhibitors as new local therapy option in primary open angle glaucoma].

Authors:  C Erb; K Konieczka
Journal:  Ophthalmologe       Date:  2021-01-05       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.